456 related articles for article (PubMed ID: 27888985)
1. Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease.
Oldham JM; Lee C; Valenzi E; Witt LJ; Adegunsoye A; Hsu S; Chen L; Montner S; Chung JH; Noth I; Vij R; Strek ME
Respir Med; 2016 Dec; 121():117-122. PubMed ID: 27888985
[TBL] [Abstract][Full Text] [Related]
2. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease.
Fischer A; Brown KK; Du Bois RM; Frankel SK; Cosgrove GP; Fernandez-Perez ER; Huie TJ; Krishnamoorthy M; Meehan RT; Olson AL; Solomon JJ; Swigris JJ
J Rheumatol; 2013 May; 40(5):640-6. PubMed ID: 23457378
[TBL] [Abstract][Full Text] [Related]
3. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
[TBL] [Abstract][Full Text] [Related]
4. Azathioprine for Connective Tissue Disease-Associated Interstitial Lung Disease.
Boerner EB; Cuyas M; Theegarten D; Ohshimo S; Costabel U; Bonella F
Respiration; 2020; 99(8):628-636. PubMed ID: 32663826
[TBL] [Abstract][Full Text] [Related]
5. Treatment of primary sjögren's syndrome-related interstitial lung disease: a retrospective cohort study.
Amlani B; Elsayed G; Barvalia U; Kanne JP; Meyer KC; Sandbo N; Li Z; McCoy SS
Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):136-147. PubMed ID: 33093777
[TBL] [Abstract][Full Text] [Related]
6. Rituximab for the treatment of connective tissue disease-associated interstitial lung disease.
Chartrand S; Swigris JJ; Peykova L; Fischer A
Sarcoidosis Vasc Diffuse Lung Dis; 2016 Jan; 32(4):296-304. PubMed ID: 26847096
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Treatment With Azathioprine and Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease.
Huapaya JA; Silhan L; Pinal-Fernandez I; Casal-Dominguez M; Johnson C; Albayda J; Paik JJ; Sanyal A; Mammen AL; Christopher-Stine L; Danoff SK
Chest; 2019 Nov; 156(5):896-906. PubMed ID: 31238042
[TBL] [Abstract][Full Text] [Related]
8. Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study.
Owen C; Ngian GS; Elford K; Moore O; Stevens W; Nikpour M; Rabusa C; Proudman S; Roddy J; Zochling J; Hill C; Sturgess A; Tymms K; Youssef P; Sahhar J
Clin Exp Rheumatol; 2016; 34 Suppl 100(5):170-176. PubMed ID: 27049330
[TBL] [Abstract][Full Text] [Related]
9. Rituximab in connective tissue disease-associated interstitial lung disease.
Duarte AC; Cordeiro A; Fernandes BM; Bernardes M; Martins P; Cordeiro I; Santiago T; Seixas MI; Ribeiro AR; Santos MJ
Clin Rheumatol; 2019 Jul; 38(7):2001-2009. PubMed ID: 31016581
[TBL] [Abstract][Full Text] [Related]
10. Treatment Outcomes for Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Real-World, Multisite Study of the Impact of Immunosuppression on Pulmonary Function Trajectory.
Matson SM; Baqir M; Moua T; Marll M; Kent J; Iannazzo NS; Boente RD; Donatelli JM; Dai J; Diaz FJ; Demoruelle MK; Hamblin MB; Mathai SK; Ryu JH; Pope K; Walker CM; Lee JS
Chest; 2023 Apr; 163(4):861-869. PubMed ID: 36470416
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease.
Swigris JJ; Olson AL; Fischer A; Lynch DA; Cosgrove GP; Frankel SK; Meehan RT; Brown KK
Chest; 2006 Jul; 130(1):30-6. PubMed ID: 16840379
[TBL] [Abstract][Full Text] [Related]
12. A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis/dermatomyositis.
Mira-Avendano IC; Parambil JG; Yadav R; Arrossi V; Xu M; Chapman JT; Culver DA
Respir Med; 2013 Jun; 107(6):890-6. PubMed ID: 23517887
[TBL] [Abstract][Full Text] [Related]
13. Idiopathic Interstitial Pneumonia Associated With Autoantibodies: A Large Case Series Followed Over 1 Year.
Collins BF; Spiekerman CF; Shaw MA; Ho LA; Hayes J; Spada CA; Stamato CM; Raghu G
Chest; 2017 Jul; 152(1):103-112. PubMed ID: 28300570
[TBL] [Abstract][Full Text] [Related]
14. Characteristics and risk factors of interstitial pneumonia with autoimmune features.
Vahidy S; Agyeman J; Zheng B; Donohoe K; Hambly N; Johannson KA; Assayag D; Fisher JH; Manganas H; Marcoux V; Khalil N; Kolb M; Ryerson CJ; ; Wong AW; Lok S; Morisset J; Fell CD; Shapera S; Gershon AS; Cox G; Halayko AJ; Sadatsafavi M; Wilcox PG; To T
Respir Med; 2024 Jan; 221():107500. PubMed ID: 38142756
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary infections following immunosuppressive treatments during hospitalization worsen the short-term vital prognosis for patients with connective tissue disease-associated interstitial pneumonia.
Tanaka M; Koike R; Sakai R; Saito K; Hirata S; Nagasawa H; Kameda H; Hara M; Kawaguchi Y; Tohma S; Takasaki Y; Dohi M; Nishioka Y; Yasuda S; Miyazaki Y; Kaneko Y; Nanki T; Watanabe K; Yamazaki H; Miyasaka N; Harigai M
Mod Rheumatol; 2015 Jul; 25(4):609-14. PubMed ID: 25496409
[TBL] [Abstract][Full Text] [Related]
16. Review series: Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ?
de Lauretis A; Veeraraghavan S; Renzoni E
Chron Respir Dis; 2011; 8(1):53-82. PubMed ID: 21339375
[TBL] [Abstract][Full Text] [Related]
17. Mean pulmonary arterial pressure as a prognostic indicator in connective tissue disease associated with interstitial lung disease: a retrospective cohort study.
Takahashi K; Taniguchi H; Ando M; Sakamoto K; Kondoh Y; Watanabe N; Kimura T; Kataoka K; Suzuki A; Ito S; Hasegawa Y
BMC Pulm Med; 2016 Apr; 16(1):55. PubMed ID: 27094018
[TBL] [Abstract][Full Text] [Related]
18. Clinical features and natural history of interstitial pneumonia with autoimmune features: A single center experience.
Chartrand S; Swigris JJ; Stanchev L; Lee JS; Brown KK; Fischer A
Respir Med; 2016 Oct; 119():150-154. PubMed ID: 27692137
[TBL] [Abstract][Full Text] [Related]
19. Current and Emerging Drug Therapies for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD).
Jee AS; Corte TJ
Drugs; 2019 Sep; 79(14):1511-1528. PubMed ID: 31399860
[TBL] [Abstract][Full Text] [Related]
20. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial.
Saunders P; Tsipouri V; Keir GJ; Ashby D; Flather MD; Parfrey H; Babalis D; Renzoni EA; Denton CP; Wells AU; Maher TM
Trials; 2017 Jun; 18(1):275. PubMed ID: 28619061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
